<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94200">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049255</url>
  </required_header>
  <id_info>
    <org_study_id>AMBES-ASTES-2013</org_study_id>
    <nct_id>NCT02049255</nct_id>
  </id_info>
  <brief_title>Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.</brief_title>
  <official_title>Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astes</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison the use of marcaine and chloroprocaine in rachianesthesia for a surgical
      correction of inguinal hernia. Comparision between acute and chronic (3 months and 6 months)
      pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Acute pain</measure>
    <time_frame>1 day of the surgery when patient leave the recovery room</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic pain</measure>
    <time_frame>at 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Marcaine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Rachianesthesia with marcaine or chloroprocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chloroprocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rachianesthesia with marcaine or chloroprocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroprocaine</intervention_name>
    <description>The Group &quot;Chloroprocaine&quot; will receive: Chloroprocaine: 50 mg in rachianesthesia</description>
    <arm_group_label>Chloroprocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Marcaine</intervention_name>
    <description>The Group &quot;Marcaine&quot; will receive: Marcaine: 12,5 mg in rachianesthesia</description>
    <arm_group_label>Marcaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults under rachianesthesia

        Exclusion Criteria:

          -  Personal history of gastric ulcus

          -  ASA 4

          -  Emergency

          -  Combined surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric P Deflandre, MD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Astes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric P DEFLANDRE, MD, FCCP</last_name>
    <phone>0032477764241</phone>
    <email>eric.deflandre@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Saint-Luc Bouge</name>
      <address>
        <city>Bouge</city>
        <state>Namur</state>
        <zip>5004</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric P Deflandre, MD, FCCP</last_name>
      <email>eric.deflandre@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 29, 2014</lastchanged_date>
  <firstreceived_date>January 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Astes</investigator_affiliation>
    <investigator_full_name>Eric DEFLANDRE, MD, FCCP</investigator_full_name>
    <investigator_title>Eric DEFLANDRE, MD, FCCP</investigator_title>
  </responsible_party>
  <keyword>All</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Inguinal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
    <mesh_term>Procaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
